Anthrax toxin fusion proteins and related methods

US5677274A · kind A · utility

Assignee

• The Government of the United States As Represented by the Department of Health and Human Services · US

Inventors

• Stephen H. Leppla · Bethesda, US
• Kurt Klimpel · Gaithersburg, US
• Naveen Arora · Hyderabad, IN
• Yogendra Singh · Cupertino, US
• Peter J. Nichols · Bexleyheath, GB

Key dates

• Filing date: Jun 25, 1993
• Grant date: Oct 14, 1997
• Expiry date: Jun 25, 2013

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16222
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the anthrax protective antigen (PA) binding domain of the native anthrax lethal factor (LF) protein and a nucleotide sequence encoding an activity inducing domain of a second protein. Also provided is a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the translocation domain and LF binding domain of the native anthrax PA protein and a nucleotide sequence encoding a ligand domain which specifically binds a cellular target. Proteins encoded by the nucleic acid of the invention, vectors comprising the nucleic acids and hosts capable of expressing the protein encoded by the nucleic acids are also provided. A composition comprising the PA binding domain of the native LF protein chemically attached to a non-LF activity inducing moiety is further provided. A method for delivering an activity to a cell is provided. The steps of the method include a) administering to the cell a protein comprising the translocation domain and the LF binding domain of the native PA protein and a ligand domain, and b) administering to the cell a product comprising t…